Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,764.40
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.11
(
-0.31%
)
Bitcoin
70,769.00
(
1.24%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Biowatch post# 2023

Monday, 11/27/2006 1:44:28 PM

Monday, November 27, 2006 1:44:28 PM

Post# of 19309
>when I said that GTCB fell on its face before, I was referring to when the FDA asked them for more clinical trial data and then GENZ abandoned them. I don't remember the name of the person I saw speak, and I'm pretty sure he's not there anymore.<

Whoever it was you saw, the person who was held responsible for the failure of GTC’s original ATryn program in CABG was the then-CEO Sandra Nusinoff Lehrman, who was canned in May, 2001. Lehrman is an MD with a background in AIDS research who probably never should have been the CEO of GTC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now